Equity Overview
Price & Market Data
Price: $2.73
Daily Change: -$0.02 / 0.73%
Range: $2.60 - $2.75
Market Cap: $3,610,042
Volume: 4,970
Performance Metrics
1 Week: 11.83%
1 Month: -45.68%
3 Months: -51.61%
6 Months: -62.14%
1 Year: -84.37%
YTD: -42.76%
Company Details
Employees: 5
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Denmark
Details
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.